Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Pembrolizumab plus enfortumab vedotin for bladder cancer

Neal Shore • 14 Feb 2021
GU Cancers 2021
Bladder Cancer Genitourinary Cancer Antibodies Enfortumab vedotin Pembrolizumab

Neal Shore, FACS, MD, Carolina Urologic Research Center, Myrtle Beach, SC, highlights a trial combining pembrolizumab with enfortumab vedotin versus pembrolizumab alone for patients with bladder cancer. This interview took place during the 2021 Genitourinary Cancers Symposium.

More from Neal Shore

0:56
KEYNOTE-676 cohort A: pembrolizumab plus BCG in recurrent HR NMIBC
Neal Shore • 26 Jan 2024
0:51
OS sensitivity analysis of darolutamide, docetaxel and ADT in ARASENS
Neal Shore • 26 Jan 2024
0:44
PROpel: gene-by-gene efficacy of olaparib and abiraterone in mCRPC
Neal Shore • 26 Jan 2024
0:39
TALAPRO-2: rPFS and OS of talazoparib and enzalutamide in mCRPC
Neal Shore • 26 Jan 2024

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals